A phase 2 study of seribantumab (MM-121) in combination with docetaxel or pemetrexed versus docetaxel or pemetrexed alone in patients with heregulin positive (HRG+), locally advanced or metastatic non-small cell lung cancer (NSCLC)

Lecia V. Sequist, Ian C. Anderson, Todd M. Bauer, Nathan Demars, Enriqueta Felip, Nikolaj Frost, Wael A. Harb, Leora Horn, Rudolf M. Huber, Art Kudla, Jeffrey Lee, Sara Mathews, Ranee Mehra, Jorge J. Nieva, M. Pérol, Frances A. Shepherd, Alexander I. Spira, Akos CzibereAnnals 2016 · DOI

BibTeX
@article{sequist2016phase,
  author = {Lecia V. Sequist and Ian C. Anderson and Todd M. Bauer and Nathan Demars and Enriqueta Felip and Nikolaj Frost and Wael A. Harb and Leora Horn and Rudolf M. Huber and Art Kudla and Jeffrey Lee and Sara Mathews and Ranee Mehra and Jorge J. Nieva and M. Pérol and Frances A. Shepherd and Alexander I. Spira and Akos Czibere},
  title = {{A phase 2 study of seribantumab (MM-121) in combination with docetaxel or pemetrexed versus docetaxel or pemetrexed alone in patients with heregulin positive (HRG+), locally advanced or metastatic non-small cell lung cancer (NSCLC)}},
  journal = {Annals},
  year = {2016},
  doi = {10.1093/annonc/mdw383.96},
}

Loading related content...

Figure